Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Aeterna Zentaris first quarter revenues increase to $7.4 million

Aeterna Zentaris first quarter revenues increase to $7.4 million

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

EntreMed reports net loss of $2.6 million for first quarter 2011

EntreMed reports net loss of $2.6 million for first quarter 2011

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Karmanos Cancer Institute raises funds for patient care and research

Karmanos Cancer Institute raises funds for patient care and research

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

Keryx Biopharmaceuticals reports net loss of $6.4 million for first quarter 2011

Keryx Biopharmaceuticals reports net loss of $6.4 million for first quarter 2011

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.